The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review

Net benefit or loss of overall discounted life expectancy for the 4 IPSS risk groups shown above and below the x-axis. A net benefit for delaying transplantation is noted for low and int-1 risk group, whereas any delay in the time to transplantation is associated with a loss in survivorship in the higher risk groups. (Reprinted with permission, Cutler et al. 2004.)

DFS among recipients of the HLA-identical related, HLA-identical unrelated, and HLA-nonidentical (related or unrelated) transplants. The + indicates censored patient. (Reprinted with permission, Deeg et al., 2002.)

OS by treatment arm for MDS. (Reprinted with permission, Couban et al., 2002.)

EFS in the RAEB/RAEB-t group according to the cell source. (Reprinted with permission, del Cañizo et al., 2003.)

Overall survival (OS) following CST and RIST in all patients. There was no significant difference in OS between CST and RIST (P = .25). (Reprinted with permission, Kojima et al. 2005.)

Cumulative survival in MDS patients (n = 1405) classified according to the FAB group proposals. (Reprinted with permission, Germing et al., 2000.)

Cumulative survival in MDS patients (n = 1157) classified according to the new WHO proposals. (Reprinted with permission, Germing et al., 2000.)